133 related articles for article (PubMed ID: 35499194)
1. Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib.
Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
J Viral Hepat; 2022 Jul; 29(7):543-550. PubMed ID: 35499194
[TBL] [Abstract][Full Text] [Related]
2. Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Kawaoka T; Aikata H; Teraoka Y; Inagaki Y; Honda F; Hatooka M; Morio K; Morio R; Kobayashi T; Nagaoki Y; Nakahara T; Hiramatsu A; Tsuge M; Imamura M; Kawakami Y; Chayama K
Oncology; 2017; 92(6):335-346. PubMed ID: 28245484
[TBL] [Abstract][Full Text] [Related]
3. Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy.
Yeh ML; Kuo HT; Huang CI; Huang CF; Hsieh MY; Liang PC; Lin IH; Hsieh MH; Lin ZY; Chen SC; Dai CY; Huang JF; Yu ML; Chuang WL
Kaohsiung J Med Sci; 2021 Feb; 37(2):145-153. PubMed ID: 33022892
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib use in hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma: A propensity score matching study.
Lee YC; Wang JH; Chen CH; Hung CH; Lo KC; Yen YH; Kee KM; Hu TH; Lu SN; Kuo YH
Kaohsiung J Med Sci; 2021 Oct; 37(10):894-902. PubMed ID: 34166565
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents.
Seko Y; Moriguchi M; Takahashi A; Yamaguchi K; Umemura A; Okuda K; Kataoka S; Unozawa H; Kobayashi K; Ogasawara S; Sato R; Tsuchiya S; Watanabe S; Morimoto N; Iwai K; Aramaki T; Kato N; Itoh Y
J Gastroenterol; 2022 Feb; 57(2):90-98. PubMed ID: 35031857
[TBL] [Abstract][Full Text] [Related]
6. Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin-bilirubin grade.
Ko CC; Ho SY; Liu PH; Hsu CY; Hsia CY; Huang YH; Su CW; Lei HJ; Lee RC; Hou MC; Huo TI
Int J Clin Oncol; 2022 Apr; 27(4):739-748. PubMed ID: 35119581
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
Ohki T; Sato K; Kondo M; Goto E; Sato T; Kondo Y; Akamatsu M; Sato S; Yoshida H; Koike Y; Obi S
J Viral Hepat; 2021 Nov; 28(11):1597-1603. PubMed ID: 34312954
[TBL] [Abstract][Full Text] [Related]
8. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
Lee PC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lee MH; Hou MC; Lee FY; Lin HC; Huang YH
Liver Int; 2018 Feb; 38(2):321-330. PubMed ID: 28736952
[TBL] [Abstract][Full Text] [Related]
9. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
Kuo YH; Wang JH; Hung CH; Rau KM; Wu IP; Chen CH; Kee KM; Hu TH; Lu SN
J Gastroenterol Hepatol; 2017 Dec; 32(12):1975-1981. PubMed ID: 28295594
[TBL] [Abstract][Full Text] [Related]
10. The Relationship between albumin-Bilirubin grade and survival in hepatocelluler carcinoma patients treated with sorefanib.
Fidan E; Fidan S; Merev E; Kazaz N
Niger J Clin Pract; 2022 Feb; 25(2):173-177. PubMed ID: 35170443
[TBL] [Abstract][Full Text] [Related]
11. CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma.
Abou-Alfa GK; Geyer SM; Nixon AB; Innocenti F; Shi Q; Kumthekar P; Jacobson S; El Dika I; Yaqubie A; Lopez J; Huang B; Tang YW; Wen Y; Schwartz LH; El-Khoueiry AB; Knox JJ; Rajdev L; Bertagnolli MM; Meyerhardt JA; O'Reilly EM; Venook AP
Cancer Res Commun; 2024 Mar; 4(3):682-690. PubMed ID: 38363156
[TBL] [Abstract][Full Text] [Related]
12. Well-controlled viremia reduces the progression of hepatocellular carcinoma in chronic viral hepatitis patients treated with lenvatinib.
Hsiao YW; Sou FM; Wang JH; Chen YH; Tsai MC; Hu TH; Hung CH; Chen CH; Kuo YH
Kaohsiung J Med Sci; 2023 Dec; 39(12):1233-1242. PubMed ID: 37843189
[TBL] [Abstract][Full Text] [Related]
13. Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients With Hepatocellular Carcinoma in Vietnam.
Nguyen TTH; Nguyen VH; Nguyen VH; Nguyen TL; Le VQ
Cancer Control; 2019; 26(1):1073274819865269. PubMed ID: 31364390
[TBL] [Abstract][Full Text] [Related]
14. Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Michitaka K; Deguchi A; Ishikawa T; Imai M; Ochi H; Joko K; Shimada N; Tajiri K; Hirooka M; Koizumi Y; Hiasa Y; Tanaka J
J Gastroenterol Hepatol; 2019 Jun; 34(6):1066-1073. PubMed ID: 30549320
[TBL] [Abstract][Full Text] [Related]
15. To treat or not to treat - Successful hepatitis C virus eradication in a patient with advanced hepatocellular carcinoma and complete response to sorafenib.
Waidmann O; Peveling-Oberhag J; Eichler K; Schulze F; Vermehren J
Z Gastroenterol; 2017 Jun; 55(6):564-568. PubMed ID: 27806410
[No Abstract] [Full Text] [Related]
16. Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status.
Lee SW; Lee TY; Peng YC; Yang SS; Yeh HZ; Chang CS
Medicine (Baltimore); 2019 Nov; 98(44):e17692. PubMed ID: 31689794
[TBL] [Abstract][Full Text] [Related]
17. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
18. Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
Ogasawara S; Chiba T; Ooka Y; Suzuki E; Kanogawa N; Saito T; Motoyama T; Tawada A; Kanai F; Yokosuka O
Invest New Drugs; 2015 Dec; 33(6):1257-62. PubMed ID: 26462681
[TBL] [Abstract][Full Text] [Related]
19. First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.
Shimose S; Hiraoka A; Nakano M; Iwamoto H; Tanaka M; Tanaka T; Noguchi K; Aino H; Ogata K; Kajiwara M; Itano S; Yokokura Y; Yamaguchi T; Kawano H; Matsukuma N; Suga H; Niizeki T; Shirono T; Noda Y; Kamachi N; Okamura S; Kawaguchi T; Koga H; Torimura T
Cancer Med; 2021 Dec; 10(23):8530-8541. PubMed ID: 34693661
[TBL] [Abstract][Full Text] [Related]
20. Effects of direct-acting antiviral therapy for patients with advanced hepatocellular carcinoma and concomitant hepatitis C-A population-based cohort study.
Tsai HY; Chang HP; Chen CJ; Hsu WL; Huang LY; Lee PC
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7543-7552. PubMed ID: 34919256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
